The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway

¹Rocío Sancho, ¹Laureano de la Vega, ²Giovanni Appendino, ³Vincenzo Di Marzo, ¹Antonio Macho & ^{*}¹Eduardo Muñoz

¹Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Facultad de Medicina, Avda. de Menéndez Pidal s/n, Córdoba 14004, Spain; ²DiSCAFF, Università del Piemonte Orientale, Viale Ferrucci 33, Novara 28100, Italy and ³Endocannabinoid Research Group, Istituto di Chimica Biomolecolare, Consiglio Nazionale delle Ricerche, Pozzuoli, Italy

1 Arvanil (*N*-arachidonoylvannillamine), a nonpungent capsaicin–anandamide hybrid molecule, has been shown to exert biological activities through VR1/CB1-dependent and -independent pathways. We have found that arvanil induces dose-dependent apoptosis in the lymphoid Jurkat T-cell line, but not in peripheral blood T lymphocytes. Apoptosis was assessed by DNA fragmentation through cell cycle and TUNEL analyses.

2 Arvanil-induced apoptosis was initiated independently of any specific phase of the cell cycle, and it was inhibited by specific caspase-8 and -3 inhibitors and by the activation of protein kinase C. In addition, kinetic analysis by Western blots and fluorimetry showed that arvanil rapidly activates caspase-8, -7 and -3, and induces PARP cleavage.

3 The arvanil-mediated apoptotic response was greatly inhibited in the Jurkat-FADD_{DN} cell line, which constitutively expresses a negative dominant form of the adapter molecule Fas-associated death domain (FADD). This cell line does not undergo apoptosis in response to Fas (CD95) stimulation.

4 Using a cytofluorimetric approach, we have found that arvanil induced the production of reactive oxygen species (ROS) in both Jurkat-FADD⁺ and Jurkat-FADD_{DN} cell lines. However, ROS accumulation only plays a residual role in arvanil-induced apoptosis.

5 These results demonstrate that arvanil-induced apoptosis is essentially mediated through a mechanism that is typical of type II cells, and implicates the death-inducing signalling complex and the activation of caspase-8. This arvanil-apoptotic activity is TRPV1 and CB-independent, and can be of importance for the development of potential anti-inflammatory and antitumoral drugs.

British Journal of Pharmacology (2003) **140**, 1035–1044. doi:10.1038/sj.bjp.0705532

Keywords: Endocannabinoid; arvanil; TRPV1; apoptosis; caspases; fas; ROS

Abbreviations: AEA, arachidonoyl ethanolamide; CB, cannabinoid receptor; DISC, death-inducing signalling complex; ERK, extracellular-signal-regulated kinase; FAAH, fatty acid amide hydrolase; FADD, Fas-associated death domain; ROS, reactive oxygen species; TRPV1, vanilloid receptor type 1; TUNEL, terminal transferase-mediated dUTP-fluorescein nick end-labelling; $\Delta\Psi_m$, mitochondria transmembrane potential

Introduction

The endocannabinoid system has raised a great interest in the last decade, because of the pleiotropic biological effects ascribed to this complex network, which is composed of cannabinoid and vanilloid receptors, metabolism-related enzymes and endogenous signalling molecules (named endocannabinoids) (De Petrocellis *et al.*, 2000; Di Marzo *et al.*, 2000a). Anandamide (*N*-arachidonoyl ethanolamide) (AEA) was the first endocannabinoid described to date, and its mechanism of action and metabolism regulation have been extensively studied in different biological models (Devane *et al.*, 1992; Di Marzo & Fontana, 1995; Lee *et al.*, 1995; Mechoulam *et al.*, 1996; De Petrocellis *et al.*, 2000). AEA is produced by neurons and other cell types from the hydrolysis of a phospholipid precursor, *N*-arachidonoyl-phosphatidylethanolamide, in a reaction catalysed by a Ca²⁺-dependent phospholipase D (Di Marzo *et al.*, 1994), and acts as a mediator in the

brain mainly by signalling through the CB₁ cannabinoid receptor. AEA is also an agonist of the vanilloid receptor type 1 (VR1 or TRPV1), a nociceptive receptor expressed preferentially in primary afferent nociceptive neurons (Zygmunt *et al.*, 1999; Smart *et al.*, 2000). TRPV1 is a nonselective cation channel gated by noxious heat, extracellular protons and either exogenous or endogenous ligands (Caterina *et al.*, 1997). Interestingly, the sensitivity of this receptor to heat and ligands is drastically increased under inflammatory conditions, and the activation of TRPV1 by lower concentrations of endogenous agonists during inflammation (including AEA) is seemingly involved in the hyperalgesia accompanying inflammation (Szallasi, 2001; Amaya *et al.*, 2003). Signal termination for AEA includes cellular reuptake by a putative AEA membrane transporter (AMT) and hydrolysis by the fatty acid amide hydrolase (FAAH) (Cravatt *et al.*, 1996; Ueda *et al.*, 2000).

Over the past few years, different strategies have been developed to increase the effectiveness and bioavailability of endocannabinoids with pharmacological potential in

*Author for correspondence; E-mail: filmuble@uco.es

Advance online publication: 6 October 2003

neurological conditions such as Parkinson's, Alzheimer's, neuropathic pain and neurological inflammation (Gubellini *et al.*, 2002; Rice *et al.*, 2002). Most of these approaches have been focused on the development of new CB agonists (Di Marzo *et al.*, 2000a), TRPV1 agonists/antagonists (Sternner & Szallasi, 1999; Appendino *et al.*, 2002) and AMT or FAAH inhibitors (Hillard & Jarrahian, 2000; Bisogno *et al.*, 2002), but also the design of new molecules that could retain activities at both CB1 and TRPV1 has been pursued.

N-(3-methoxy-4-hydroxy-benzyl)-arachidonoylamide (arvanil) was designed in an attempt to obtain a hybrid metabolically stable TRPV1/CB1 ligand with a pharmacological profile suitable for the development of ultrapotent analgesics (Di Marzo *et al.*, 2002). Arvanil is a 'chimeric' ligand that combines the structural features of capsaicin and anandamide, namely the vanillyl moiety of capsaicin and the arachidonoyl group of anandamide. Arvanil has an affinity for CB1 receptors comparable to, or lower than, that of AEA, and also activates TRPV1 more potently than capsaicin or AEA (Melck *et al.*, 1999). Moreover, arvanil is one of the most potent AMT inhibitors developed to date and also inhibits FAAH, the enzyme responsible for the hydrolysis of AEA and other endocannabinoids (Glaser *et al.*, 2003). In addition, arvanil has been suggested to induce CB/TRPV1-independent biological effects *in vivo* (Di Marzo *et al.*, 2000b; Brooks *et al.*, 2002).

Programmed cell death, or apoptosis, is a genetically controlled mechanism playing an important role in the regulation of cellular homeostasis. Many triggers can induce apoptosis, including the stimulation of cell membrane-bound receptors (reviewed in Timmer *et al.*, 2002). Among them, CD95 (APO-1, Fas) is an important member of the tumour necrosis factor receptor superfamily (reviewed in Wallach *et al.*, 1997) expressed in many different tissues, including T cells, playing a fundamental role in the homeostasis of the immune system (Kroemer & Martinez, 1994). The CD95 signalling pathway has been explored by biochemical and genetic approaches, and it is activated by direct interaction with CD95L (a physiological ligand) or by cytotoxic drugs (Micheau *et al.*, 1999). Upon CD95 stimulation and trimerization, a set of proteins is recruited to this receptor, leading to the formation of the death-inducing signalling complex (DISC) (Kischkel *et al.*, 1995), which contains the intracellular adapter protein FADD that binds to the death domain of the CD95 receptor and to caspase-8, inducing its proteolytic activation. Caspase-8, in turn, activates a proteolytic caspase cascade that transmits and amplifies death signals by the activation of apoptotic executioner caspases such as caspase-3 and -7. These executioner caspases cleavage several substrate proteins including poly(ADP ribose)polymerase (PARP), resulting in the self-destruction of the cells (reviewed in Cryns & Yuan, 1998).

CD95-induced apoptosis is executed by at least two different signalling pathways. In type I cells, large amounts of caspase-8 are recruited to and activated at the DISC, immediately followed by the activation of caspase-3 prior to loss of the mitochondrial transmembrane potential $\Delta\Psi_m$ (Scaffidi *et al.*, 1998). In type II cells, the DISC formation is less evident and Bid, a substrate of caspase-8, is cleaved to generate a proapoptotic form, tBid, that targets the mitochondria, allowing the release of cytochrome *c*, which is an essential

cofactor for caspase-3 activation (Li *et al.*, 1998; Budd, 2002). The truncated proapoptotic form of Bid complexes and inhibits Bcl-2 in the outer mitochondria membrane, leading to the release of cytochrome *c* without a disruption of the $\Delta\Psi_m$ (reviewed in Scaffidi *et al.*, 1998; Kim *et al.*, 2000).

Since anandamide and capsaicin have been shown to induce apoptosis in different cell types (Macho *et al.*, 1999; Lee *et al.*, 2000; Maccarrone *et al.*, 2000; Sarker *et al.*, 2000; Jung *et al.*, 2001), we were interested in studying the apoptotic effect of the AEA–capsaicin hybrid arvanil in both peripheral T cells and in a lymphoma T-cell line widely used as a model for T-cell signalling. We present evidence that arvanil induces apoptosis in the Jurkat cell line but not in T resting cells. DNA fragmentation and PARP cleavage in arvanil-treated cells are preceded by the activation of caspase-8, -3 and -7, and are apparently independent of CB and TRPV1 signalling pathways. We also demonstrate that arvanil-induced apoptosis is mediated by a pathway that involves DISC formation.

Methods

Cell lines and reagents

Jurkat cells (ATCC, Rockville, MD, U.S.A.) were maintained in exponential growth in RPMI 1640 medium (Gibco, Paisley, Scotland) supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine and the antibiotics penicillin and streptomycin (Gibco). The Jurkat-FADD_{DN} cell line is a Jurkat-derived clone stably transfected with an expression vector encoding a dominant-negative form of the FADD protein (Hofmann *et al.*, 2001), and was maintained in complete medium containing 100 $\mu\text{g ml}^{-1}$ of G418. The cell-permeable inhibitors of caspases zDEVD-fmk and zETD-fmk (*N*-benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethyl ketone and *N*-benzyloxycarbonyl-Ile-Glu-Thr-Asp-fluoromethyl ketone, respectively) were from Bachem (Bubendorf, Switzerland). FITC-12-deoxy-2-uridine triphosphate (FITC-dUTP) and terminal deoxynucleotidyl-transferase (TdT) were from Roche (Mannheim, Germany). The rabbit polyclonal α -caspase-3 was from Dako Diagnostic (Copenhagen, Denmark), the antisera α -caspase-7, α -caspase-8 and anti-PARP were from Chemicon (Harrow, U.K.), the mAb anti-CD95 was from Pharmingen (San Antonio, CA, U.S.A.) and the mAb anti-tubulin was from Sigma Chemical Co. (Barcelona, Spain). Arvanil was either purchased (Alexis, Carlsbad, CA, U.S.A.) or synthesized according to a recently published procedure for the acylation of vanillamine (Appendino *et al.*, 2002). In short, a cooled (0°C) solution of arachidonic acid (99%, purchased from Alexis) in dry dichloromethane was sequentially treated with vanillamine hydrochloride (1 mol. equiv.), triethylamine (2 mol. equiv.) and propylphosphonic acid anhydride (PPAA, 50% solution in ethyl acetate, 2 mol. equiv.). After stirring for 15 min at 0°C, the reaction was worked up by evaporation, and arvanil was purified by a short column of silica gel using petroleum ether-ethyl acetate 9:1 as eluant. Typical yields were in the range of 70–79%. Arvanil was dissolved in ethanol and the stock solution was prepared at 10 mM and stored at –20°C. The maximum final concentration of the solvent in the cell cultures was 0.25%, which did not affect any of the parameters

analysed in this study. All other reagents not cited above or later were from Sigma Chemical Co.

Isolation of peripheral human T cells

Human PBMC, from healthy adult volunteer donors, were isolated by centrifugation of venous blood on Ficoll-Hypaque[®] density gradients (Pharmacia LKB Biotechnology, Piscataway, NJ, U.S.A.). Macrophages were removed by incubating the PBMC on 100 mm plastic Petri plates at 37°C for 60 min, and the remaining cells were passed twice through a nylon wool column to deplete residual B cells and macrophages. Nylon wool T cells were usually 95% CD3⁺ and less than 5% CD25⁺.

Determination of nuclear DNA loss and cell cycle analysis

The percentage of cells undergoing chromatinolysis (subdiploid cells) was determined by ethanol fixation (70% for 24 h at 4°C). Then, the cells were washed twice with phosphate-buffered saline (PBS) containing 4% glucose, and subjected to RNA digestion (RNase-A, 50 U ml⁻¹) and PI (20 µg ml⁻¹) staining in PBS for 1 h at RT, and analysed by cytofluorimetry. With this method, low molecular weight DNA leaks from the ethanol-fixed apoptotic cells and the subsequent staining allows the determination of the percentage of subdiploid cells (sub-G₀/G₁ fraction).

Detection of DNA strand breaks by the TUNEL method

Cells (1 × 10⁶) were fixed in 4% paraformaldehyde in PBS for 24 h at 4°C, washed twice in PBS and permeabilized in 0.1% sodium citrate containing 0.1% Triton X-100 for 20 min. Fixed cells were washed three times in PBS and resuspended in a final volume of 50 µl of TUNEL buffer (0.3 nmol FITC-dUTP, 3 nmol dATP, 50 nmol CoCl₂, 5 U TdT, 200 mM potassium cacodylate, 250 µg ml⁻¹ BSA and 25 mM Tris-HCl pH 6.6). The cells were incubated for 1 h at 37°C and then washed twice in PBS and analysed by flow cytometry. To determine both DNA strand breaks and cell cycle, TUNEL-stained cells were counterstained with PI and treated with RNase, as described above, prior to cytofluorometric analysis. In this method, fixation in formaldehyde prevents the extraction of low molecular weight DNA from apoptotic cells and thus the cell cycle distribution estimates both apoptotic and nonapoptotic cells.

Determination of caspase-3 and -8 activity

Jurkat cells (3 × 10⁶) were washed with PBS and incubated for 30 min on ice with 100 µl of lysis buffer (10 mM Tris-HCl, 10 mM NaH₂PO₄/NaHPO₄, pH 7.5, 130 mM NaCl, 1% Triton[®] X-100 and 10 mM sodium pyrophosphate). Cell lysates were spun, the supernatants collected and the protein concentrations determined by the Bradford method. For each reaction, 30 µg of protein from cell lysates was added to 1 ml of freshly prepared protease assay buffer (20 mM HEPES pH 7.5, 10% glycerol, 2 mM DTT) containing 15 µg of either Ac-DEVD-AMC or Ac-IETD-AMC (Sigma Chemical Co.). Reaction mixtures in the absence of cellular extracts were used as negative controls (fluorescence background). Reaction mixtures were incubated for 1 h at 37°C and

the AMC liberated from Ac-peptides-AMC was measured using a spectrofluorimeter (Hitachi F-2500 model, Hitachi Ltd, Tokyo, Japan) with an excitation wavelength of 380 nm and an emission wavelength range of 400–550 nm. Data were collected as the integer of relative fluorescence intensity (RFI) minus the background fluorescence, and represented as RFI-fold induction ± s.d. over untreated control.

Determination of ROS generation

To study the superoxide anion generation (ROS), cells were incubated (10⁶ ml⁻¹) in PBS with dihydroethidine (HE) (red fluorescent after oxidation) (2 µM) (Sigma) for 20 min at 37°C, followed by analysis on an Epics XL Analyzer (Coulter, Hialeah, FL, U.S.A.).

Transient transfections and luciferase assays

Jurkat cells (10⁷ ml⁻¹) were transiently transfected with a construct containing the luciferase gene driven by a 2.3 kb fragment of FasL promoter (pxp2-FasL) that was kindly provided by J.A. Pintor-Toro (CSIC, Sevilla, Spain). The transfections were performed using Lipofectine[™] reagent (Invitrogen, Barcelona, Spain), according to the manufacturer's recommendations, for 24 h. Transfected cells were treated as indicated for 6 h. Then, the cells were lysed in 25 mM Tris-phosphate pH 7.8, 8 mM MgCl₂, 1 mM DTT, 1% Triton X-100 and 7% glycerol. Luciferase activity was measured using an Autolumat LB 953 (EG&G Berthold, U.S.A.), following the instructions of the luciferase assay kit (Promega, Madison, WI, U.S.A.), and protein concentration was measured by the Bradford method. The background obtained with the lysis buffer was subtracted in each experimental value and the specific transactivation expressed as a fold induction over untreated cells. Data are represented as mean ± s.e. of three independent experiments.

Western blots

Jurkat cells (1 × 10⁶ cells ml⁻¹) were stimulated with different concentrations of arvanil for the indicated period of times. Cells were then washed with PBS and resuspended in 50 µl of lysis buffer (20 mM HEPES pH 8.0, 10 mM KCl, 0.15 mM EGTA, 0.15 mM EDTA, 0.5 mM Na₃VO₄, 5 mM NaF, 1 mM DTT, leupeptin 1 µg ml⁻¹, pepstatin 0.5 µg ml⁻¹, aprotinin 0.5 µg ml⁻¹ and 1 mM PMSF) containing 0.5% NP-40. After 15 min on ice, cytoplasmic proteins were obtained by centrifugation and protein concentration determined by a Bradford assay (Bio-Rad, Richmond, CA, U.S.A.). The proteins (30 µg) were boiled in Laemmli buffer and electrophoresed in 10% SDS–polyacrylamide gels. Separated proteins were transferred to nitrocellulose membranes (0.5 A at 100 V; 4°C) for 1 h. The blots were blocked in TBS solution containing 0.1% Tween 20 and 5% nonfat dry milk overnight at 4°C, and immunodetection of specific proteins was carried out with primary antibodies (anticaspase-3, anticaspase-7, anticaspase-7, anti-PARP or anti-α-tubulin), using an ECL system (Amersham, U.K.).

Results

Arvanil induces apoptosis in Jurkat cells but not in primary T cells

The effect of arvanil on cellular apoptosis was investigated in the leukaemia cell line Jurkat and in human purified primary T cells. The cells were incubated with arvanil (25 μ M) for 6 h and the hypodiploidy (i.e., loss of fragmented DNA) was detected by flow cytometry as a marker for apoptosis. In Figure 1a, it is shown that arvanil was able to induce a strong increase in the percentage of hypodiploid cells. However, when human purified primary T cells were treated with the same concentra-

Figure 1 Arvanil induces apoptosis in Jurkat cells but not in primary T cells. (a) Cell cycle analysis. Cells were treated with increasing concentrations of arvanil for 6 h and the percentage of hypodiploid cells was detected using flow cytometry. Results are representative of three independent experiments. (b) Jurkat cells (black bars) or human peripheral isolated T cells (grey bars) were treated with arvanil at the indicated doses for 6 h, and the percentage of hypodiploid cells determined by flow cytometry. The percentage of vehicle (v/v) used in each treatment is indicated. Values are means $\pm$ s.e. of three different experiments.

tion of arvanil, we could not detect a significant increase in the percentage of hypodiploidy cells. While ethanol did not affect the cell cycle, arvanil-induced hypodiploidy in Jurkat cells was dose-dependent and it was already detected with the lower concentration tested (Figure 1b). Next, to examine whether arvanil-induced apoptosis in Jurkat cells is dependent on a specific phase of the cell cycle, we performed double-staining experiments with PI and FITC-dUTP, as described in Methods. In this way, the phase of the cell cycle during which DNA fragmentation occurs can be established. In Figure 2, it is shown that arvanil-induced DNA fragmentation (68.6% of the cells) appeared to be proportional to the number of cells in each phase of the cell cycle. Thus, in contrast to the results obtained by cell treatment with podophylotoxin, a compound that binds tubulin and arrests cell cycle at the G₂/M phase initiating the DNA fragmentation, arvanil-induced apoptosis was independent of any specific phase of the cell cycle. This result could explain the different percentages of apoptotic cells found by using either cell cycle analysis by PI staining (52% in Figure 1a) or the TUNEL method (68% in Figure 2).

Apoptosis induced by arvanil in Jurkat cells involves the caspase cascade pathway

The caspase family consists of postaspartate-cleaving cysteine proteases that have been shown to be required for apoptosis in a number of experimental systems (reviewed in Thornberry & Lazebnik, 1998). Thus, to study the activation of the executor caspase-3 and the modulator caspase-8 in a direct way, we incubated the cells with arvanil (15 μ M) for different periods of time, and the activities of both caspases were determined by a fluorimetric method that is highly specific and sensitive. Figure 3a shows that the treatment of Jurkat cells with arvanil led to the activation of both caspases, with a very similar kinetic showing a maximal activation after 6 h of treatment. Next, to establish the involvement of caspase activation in arvanil-mediated apoptosis of Jurkat cells, we preincubated the cells with either of the tetrapeptide caspase inhibitors zDEVD-fmk or zIETD-fmk before arvanil treatment. zDEVD-fmk and zIETD-fmk are reported to inhibit caspase-3 and -8, respectively. The percentage of apoptotic cells was determined 6 h after arvanil treatment by the TUNEL method, and in Figure 3b it is shown that apoptosis induced by arvanil was largely inhibited by both caspase inhibitors. It is

Figure 2 TUNEL analysis of arvanil-induced apoptosis. Jurkat cells were treated either with arvanil 25 μ M for 6 h or podophylotoxin 10 μ M for 24 h, and the cell cycle and the DNA strand breaks analysed using flow cytometry, as described in Methods. The continuous horizontal line divides the diagram into fragmented DNA cells (upper square) and nonfragmented DNA cells (lower square), and vertical dash lines separate each phase of the cell cycle: Go/G1 (left), S (middle) and G2/M (right). Numbers represent the percentage of cells in each group. Results are representative of three different experiments.

Figure 3 Involvement of caspase activation in arvanil-induced apoptosis. (a) Caspase activity determination. Jurkat cells were treated with arvanil (15 μ M) and the kinetics of caspase-3 and -8 activation detected by fluorimetry. (b) DNA fragmentation analysis in the presence of caspase-3 and -8 inhibitors. Cells were preincubated with 20 μ M of the caspase inhibitors zDEVD-fmk (for caspase-3) and zIETD-fmk (for caspase-8), and treated with arvanil 15 μ M for 6 h. After this time, DNA fragmentation was detected by the TUNEL method. Values are means $\pm$ s.e. of three different experiments. (c) Kinetic studies of caspase-8, -3 and -7 activation and PARP cleavage by Western blot. Cells were treated with arvanil 15 μ M at the indicated times and the steady-state protein levels of caspase-3, -8, -7, PARP and α -tubulin detected by Western blot. (d) Dose-response effects of arvanil (6 h) on the proteolytic degradation of caspase-3, -8 and -7.

noteworthy that zDEVD-fmk was slightly more effective at protecting Jurkat cells from arvanil-induced apoptosis than zIETD-fmk. These results demonstrate a role for caspase-8 in the apoptotic pathway activated by arvanil, and, since this caspase triggers a proteolytic cascade that amplifies death signals by the activation of executioner caspase-3 and -7, we were interested in examining if arvanil could also induce the activation of caspase-7 in Jurkat cells. This caspase was

present in control Jurkat cells primarily as a 35 kDa protein (Figure 3c). Treatment with arvanil (15 μ M) resulted in a time-dependent processing of caspase-7, accompanied by the formation of one major product of about 32 kDa, which probably represents the loss of the prodomain at DSVD²³. Processing of caspase-7 was first observed 1 h after arvanil treatment and it was completed at 6 h of treatment. Similar kinetics of activation was found for caspase-3 and -8 in arvanil-treated cells. However, although PARP cleavage was initiated after 1 h treatment, the maximum cleavage was reached after 6 h of treatment with arvanil. In addition, arvanil-induced processing of the three procaspase forms was found to be dose-dependent, being detectable with 10 μ M arvanil, a concentration at which apoptosis is already detectable (Figure 3d). Arvanil treatment did not affect the steady-state levels of the housekeeping protein α -tubulin.

FADD-dependent caspase activation is required for arvanil-induced apoptosis in Jurkat cells

It is accepted that Fas (CD95) signaling pathway is mediated by recruitment of FADD and procaspase-8 to the death domain of Fas to form the DISC (Kischkel *et al.*, 1995; reviewed in Timmer *et al.*, 2002). The involvement of further DISC protein for arvanil-induced apoptotic pathway was investigated by analysing CD95 and arvanil-induced apoptosis in a Jurkat line stably expressing a dominant-negative form of the FADD (FADD_{DN}) adapter protein, which lacks the death effector domain (Hofmann *et al.*, 2001). Overexpression of FADD_{DN} prevents DISC formation and activation of caspase-8 triggered by FasL or anti-Fas antibodies (Chinnaiyan *et al.*, 1996). In Figure 4a, it is shown that either anti-CD95 or arvanil induce DNA fragmentation in the parental Jurkat cells; by contrast, in the Jurkat-FADD_{DN}, no apoptosis was found in response to the agonist mAb anti-CD95. Arvanil-induced apoptosis was also largely inhibited in the FADD_{DN} cells although a residual apoptosis was observed with the higher doses of arvanil tested. Activation of caspase-3 and -8 was also impaired in Jurkat-FADD_{DN} when compared with the Jurkat wild type and, again, some degree of caspase activation could be detected in arvanil-treated Jurkat-FADD_{DN} cells (Figure 4b). These results suggest that an additional pathway independent of FADD is also activated by arvanil in Jurkat cells. A number of previous studies have reported that in type II cells PMA treatment inhibits Fas-mediated apoptosis (reviewed in Krammer, 2000). In this sense, the inhibitory effect on PMA-induced apoptosis can be mediated by disrupting DISC formation or by activation of the ERK pathway (Ruiz-Ruiz *et al.*, 1999; Meng *et al.*, 2002). Thus, to investigate the role of PKC in arvanil-induced apoptosis, Jurkat cells were stimulated with the PKC agonist PMA for 30 min prior to treatment with arvanil. Then, DNA fragmentation was measured, and in Figure 5a it is shown that PMA pretreatment almost abolished the apoptosis induced by arvanil, which also correlated with the ability of PMA to inhibit arvanil-induced activation of caspase-3 and -8 (Figure 5b).

Arvanil does not induce FasL transcriptional activity

It has been shown that some cytotoxic drugs can induce Fas-mediated apoptosis by upregulation of the FasL gene (Pucci

Figure 4 Arvanil-induced apoptosis is impaired in Jurkat-FADD_{DN} cells. (a) DNA fragmentation. Jurkat and Jurkat FADD_{DN} cells were treated with either anti-CD95mAb or arvanil (10 and 15 μ M) for 6 h, and the percentage of apoptotic cells (DNA fragmentation) was detected by TUNEL staining and flow cytometry (b). Fluorimetric analysis of caspase-3 and -8 activities in Jurkat and Jurkat FADD_{DN} cells treated with arvanil (15 μ M) for 6 h. Data are represented as the means of RFI fold induction over untreated control $\pm$ s.e. of three different experiments.

Figure 5 PMA inhibits arvanil-induced apoptosis and caspase-3 and -8 activation. (a) Jurkat T cells were preincubated with either zIETD (20 μ M) or PMA (20 nM), and treated with arvanil 15 μ M for 6 h. The percentage of apoptosis was determined as in Figure 3b. (b) Caspase-3 and -8 activity detection by fluorimetry in cells treated with arvanil in the presence or absence of PMA.

et al., 1999; Mansouri *et al.*, 2003). Since FasL expression is tightly regulated at the transcriptional level, we investigated the regulation of the FasL promoter in Jurkat cells transiently

Figure 6 Arvanil does not affect FasL gene expression. Jurkat cells were transiently transfected with the pxp2-FasL-luc plasmid, as described in Methods. At 24 h post-transfection, cells were treated with either TNF α or with arvanil at the indicated doses for 3 h. Then, the cells were lysed and the luciferase activity measured. Values are means of RLU fold induction $\pm$ s.e. of three independent experiments.

transfected with the promoter reporter plasmid pxp2-FasL-Luc. After transfection, cells were treated either with TNF α or with increasing concentrations of arvanil for 3 h, to ensure that the measurement of luciferase activity is not affected by arvanil-induced DNA fragmentation. In Figure 6, it is shown that the TNF α -responsive FasL promoter was not upregulated by arvanil with any of the concentrations tested. Altogether, these results strongly suggest that although arvanil-induced apoptosis is mainly dependent on FADD, clustering of CD95 by FasL binding is not necessary.

Arvanil induces sequential ROS generation in Jurkat cells

Arvanil is a nonpungent anandamide–capsaicin hybrid that contains the vanilloid ring (Melck *et al.*, 1999). We have previously shown that vanilloid compounds behave as quinone analogues and induce intracellular ROS and apoptosis in Jurkat cells (Macho *et al.*, 1998; 1999; 2000; 2003). Thus, we studied the ability of arvanil to generate ROS using HE (nonfluorescent) that becomes ethidium (Eth, red fluorescent) after its oxidation *via* ROS (Petit *et al.*, 1990). We treated both Jurkat and Jurkat-FADD_{DN} cells with arvanil (10 μ M) for 6 h, and the percentage of cells with high levels of intracellular ROS was analysed by flow cytometry (Figure 7a). We observed that ROS increase in both cell lines treated with this compound was dose-dependent (Figure 7b). Interestingly, when cell death was measured in parallel in arvanil-treated cells, Jurkat-FADD_{DN} cells were clearly more resistant to cell death than the parental clone (Figure 7c). These differences suggest that ROS generation could be implicated in a part of arvanil-induced apoptosis, but not in the whole process, a fact that could explain the residual albeit significant apoptosis observed in arvanil-treated Jurkat-FADD_{DN} cells (Figure 4a).

Discussion

It is now widely accepted that in addition to their cannabinimimetic effects, AEA and other endocannabinoids have pleiotropic activities (reviewed in Parolaro *et al.*, 2002). Thus, AEA has been implicated in the regulation of cell growth and differentiation (reviewed in Parolaro *et al.*, 2002) and, more recently, cannabinoids have been shown to play an important role in the angiogenic process accompanying tumoral spread and invasion (Blazquez *et al.*, 2003; Casanova *et al.*, 2003), suggesting a possible antitumoral activity for the endocannabinoid system (reviewed in Bifulco & Di Marzo, 2002). Accordingly, there is growing evidence that AEA, and perhaps other arachidonic acid derivatives as well, may exert a control on cellular growth and apoptosis through different signal pathways. In this sense, metabolically stable analogues of AEA like arvanil might be of special interest in studying the mechanistic aspects of the apoptotic properties of endocannabinoids and endovanilloids.

Arvanil is a capsaicin–anandamide hybrid with a very high structural homology to the recently described endovanilloid *N*-arachidonoyl dopamine (NADA) (Bisogno *et al.*, 2000; Huang *et al.*, 2002). Arvanil and NADA are TRPV1 and CB1 receptor agonists, and lack CB2 agonist activity. Since Jurkat cells do not express neither TRPV1 or CB1 receptors (Sancho *et al.*, 2003), we assumed that arvanil-induced apoptosis is through TRPV1 and CB receptor-independent pathways. Our results strongly suggest that DISC formation and activation of caspase-8 are the initial steps in arvanil-induced apoptosis and, although arvanil did not upregulate FasL, it is likely that arvanil induces Fas clustering and DISC formation, since stably FADD_{DN}-transfected Jurkat cells showed a clear diminished caspase-8 and -3 activation and DNA fragmentation in response to this compound. Moreover, the effects of arvanil on DISC formation were supported by our results showing that PKC activation protects from arvanil-induced apoptosis. It has been demonstrated that in type II (e.g., Jurkat) cells, PKC activation prevents CD95-mediated apop-

Figure 7 Arvanil induces ROS formation in both Jurkat and Jurkat-FADD_{DN} cell lines. (a) Jurkat or Jurkat-FADD_{DN} cells were treated with arvanil 15 μ M, and after 6 h they were collected and the percentage of cells with high Eth fluorescence (ROS generation) detected by flow cytometry (b, c). Dose–response generation of ROS (b) and cell death (c) in arvanil-treated Jurkat and Jurkat-FADD_{DN} cells for 6 h. Values are means $\pm$ s.e. of three different experiments.

toxis by inhibiting CD95 receptor oligomerization at the cell membrane, thus avoiding DISC formation (Ruiz-Ruiz *et al.*, 1999). In addition, PMA activates the ERK pathway that

Figure 8 Schematic diagram highlighting the proposed mechanism for arvanil-induced apoptosis. Arvanil induces FADD clustering, which allows the recruitment of caspase-8. Then, this caspase is cleaved and activated, leading to an apoptotic cascade that includes Bid truncation, leaking of cytochrome *c* from mitochondria and activation of different effector caspases (-3, -7, -9). To complement this pathway, arvanil induces ROS that may help to DISC formation and may also induce the mitochondrial release of cytochrome *c*.

prevents apoptosis and promotes cell survival (Scaffidi *et al.*, 1999). Altogether, our results indicate that arvanil induces an apoptosis that is typical of type II cells by a FasL-independent mechanism (Figure 8).

Although a high percentage of human primary T cells express CD95, our results show that arvanil does not induce apoptosis in these cells. The arachidonic acid moiety of arvanil may allow the molecule to enter the cells by a process of simple diffusion, as it has been recently suggested for AEA (Glaser *et al.*, 2003). Like other antitumour lipids (Cabaner *et al.*, 1999), the cellular uptake of arvanil could be much larger in tumoral cells than in primary resting T cells. In addition, primary resting T cells could be more resistant to anti-CD95-mediated apoptosis than Fas-expressing cultured cell lines, as previously proposed (Miyawaki *et al.*, 1992). Thus, our results suggest that, in addition to CD95/Fas expression, other cellular factors may be required for arvanil-induced apoptosis.

We and others have demonstrated that the vanilloid moiety of resiniferatoxin, capsaicin and capsiate behaves as a quinone analogue, targeting and inhibiting the plasma membrane redox system (Vaillant *et al.*, 1996; Wolvetang *et al.*, 1996; Macho *et al.*, 1999). As a result of this inhibition, quinone analogues generate an excess of intracellular ROS that contributes to the

apoptotic pathway (Hildeman *et al.*, 1999). Here we show that arvanil, which contains a vanilloid moiety, can also behave as a quinone analogue, since it was able to induce high levels of intracellular ROS in either Jurkat or Jurkat FADD_{DN} cell lines. However, the fact that Jurkat FADD_{DN} cells were highly resistant to arvanil-induced apoptosis compared to the wild-type clone suggests that ROS generation could be implicated in arvanil-induced apoptosis by at least two pathways. First, arvanil-induced ROS may activate a sphingomyelinase at the lipid rafts of the cell membrane, increasing the intracellular levels of ceramide (reviewed in Andrieu-Abadie *et al.*, 2001), which has been involved in the apoptotic pathways induced by a wide range of stimuli including Fas (reviewed in Carmody & Cotter, 2001). Then, ceramide could favour DISC assembly triggering the apoptotic cascade. This hypothesis will be in concordance with a recent report showing that Fas-resistant cell lines (like our Jurkat FADD_{DN} cell clone) are also resistant to apoptosis induced by either serum withdrawal or exogenous ceramide (Caricchio *et al.*, 2002). Secondly, ROS may also induce a direct attack to the mitochondria pores, inducing the release of cytochrome *c* and further activation of executor caspases (Macho *et al.*, 1998). This second pathway could explain the residual albeit significant cell death observed in arvanil-treated Jurkat-FADD_{DN} cells, which was due to apoptosis rather than necrosis.

Anandamide transport inhibitors and FAAH inhibitors are designed to increase AEA concentrations outside the cells, thus enhancing its biological effects. For instance, it has been shown that both AMT and FAAH inhibitors (AM404 and ATFMK, respectively) enhance the apoptotic effects of AEA in human neuroblastoma CHP100 and lymphoma U937 cells (Maccarrone *et al.*, 2000). Recently, it has also been reported that arvanil inhibits AEA transport into cells by targeting FAAH (Glaser *et al.*, 2003), and, although Jurkat cells express FAAH (Sancho *et al.*, 2003), we found that its pharmacological inhibition with arachidonoyl trifluoromethyl ketone (ATFMK) did not induce apoptosis in this particular cell line (data not shown), ruling out the possible involvement of this enzyme in arvanil-induced apoptosis.

In conclusion, we have demonstrated that arvanil induces apoptosis in lymphoid cells through a FADD-mediated mechanism that involves the activation of caspase-8, -3 and -7. This activity might underlie some of the known anti-inflammatory and proapoptotic effects of endocannabinoids/endovanilloids, and provides a rationale for the synthesis of new analogues endowed with selective anti-inflammatory and anticancer properties.

This work was supported by the grants BIO 2000-1091-C01 (MCyT) and QLK3-CT2000-00463 (UE) to E.M., and by the MCyT grant SAF2002-01157 to A.M. We thank Dr Lienhard Schmitz (University of Bern, Switzerland) for providing the stably transfected Jurkat-FADD_{DN} cell line.

References

- AMAYA, F., OH-HASHI, K., NARUSE, Y., IJIMA, N., UEDA, M., SHIMOSATO, G., TOMINAGA, M., TANAKA, Y. & TANAKA, M. (2003). Local inflammation increases vanilloid receptor 1 expression within distinct subgroups of DRG neurons. *Brain Res.*, **963**, 190–196.
- ANDRIEU-ABADIE, N., GOUAZE, V., SALVAYRE, R. & LEVADE, T. (2001). Ceramide in apoptosis signaling: relationship with oxidative stress. *Free Radic. Biol. Med.*, **31**, 717–728.

- APPENDINO, G., MINASSI, A., MORELLO, A.S., DE PETROCELLIS, L. & DI MARZO, V. (2002). N-Acylvanillamides: development of an expeditious synthesis and discovery of new acyl templates for powerful activation of the vanilloid receptor. *J. Med. Chem.*, **45**, 3739–3745.
- BIFULCO, M. & DI MARZO, V. (2002). Targeting the endocannabinoid system in cancer therapy: a call for further research. *Nat. Med.*, **8**, 547–550.

- BISOGNO, T., DE PETROCELLIS, L. & DI MARZO, V. (2002). Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. *Curr. Pharm. Des.*, **8**, 533–547.
- BISOGNO, T., MELCK, D., BOBROV, M., GRETSKAYA, N.M., BEZUGLOV, V.V., DE PETROCELLIS, L. & DI MARZO, V. (2000). N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity *in vitro* and *in vivo*. *Biochem. J.*, **351** (Part 3), 817–824.
- BLAZQUEZ, C., CASANOVA, M.L., PLANAS, A., DEL PULGAR, T.G., VILLANUEVA, C., FERNANDEZ-ACENERO, M.J., ARAGONES, J., HUFFMAN, J.W., JORCANO, J.L. & GUZMAN, M. (2003). Inhibition of tumor angiogenesis by cannabinoids. *FASEB J.*, **17**, 529–531.
- BROOKS, J.W., PRYCE, G., BISOGNO, T., JAGGAR, S.I., HANKEY, D.J., BROWN, P., BRIDGES, D., LEDENT, C., BIFULCO, M., RICE, A.S., DI MARZO, V. & BAKER, D. (2002). Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors. *Eur. J. Pharmacol.*, **439**, 83–92.
- BUDD, R.C. (2002). Death receptors couple to both cell proliferation and apoptosis. *J. Clin. Invest.*, **109**, 437–441.
- CABANER, C., GAJATE, C., MACHO, A., MUNOZ, E., MODOLELL, M. & MOLLINEDO, F. (1999). Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-0CH3: involvement of the Fas receptor/ligand system. *Br. J. Pharmacol.*, **127**, 813–825.
- CARICCHIO, R., D'ADAMIO, L. & COHEN, P.L. (2002). Fas, ceramide and serum withdrawal induce apoptosis *via* a common pathway in a type II Jurkat cell line. *Cell Death Differ.*, **9**, 574–580.
- CARMODY, R.J. & COTTER, T.G. (2001). Signalling apoptosis: a radical approach. *Redox Rep.*, **6**, 77–90.
- CASANOVA, M.L., BLAZQUEZ, C., MARTINEZ-PALACIO, J., VILLANUEVA, C., FERNANDEZ-ACENERO, M.J., HUFFMAN, J.W., JORCANO, J.L. & GUZMAN, M. (2003). Inhibition of skin tumor growth and angiogenesis *in vivo* by activation of cannabinoid receptors. *J. Clin. Invest.*, **111**, 43–50.
- CATERINA, M.J., SCHUMACHER, M.A., TOMINAGA, M., ROSEN, T.A., LEVINE, J.D. & JULIUS, D. (1997). The capsaicin receptor – a heat-activated ion-channel in the pain pathway. *Nature*, **389**, 816–824.
- CHINNAIYAN, A.M., TEPPER, C.G., SELDIN, M.F., O'ROURKE, K., KISCHKEL, F.C., HELLBARDT, S., KRAMMER, P.H., PETER, M.E. & DIXIT, V.M. (1996). FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. *J. Biol. Chem.*, **271**, 4961–4965.
- CRAVATT, B.F., GIANG, D.K., MAYFIELD, S.P., BOGER, D.L., LERNER, R.A. & GILULA, N.B. (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. *Nature*, **384**, 83–87.
- CRYSNS, V. & YUAN, J. (1998). Proteases to die for. *Genes. Dev.*, **12**, 1551–1570.
- DE PETROCELLIS, L., MELCK, D., BISOGNO, T. & DI MARZO, V. (2000). Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. *Chem. Phys. Lipids*, **108**, 191–209.
- DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science*, **258**, 1946–1949.
- DI MARZO, V., BISOGNO, T. & DE PETROCELLIS, L. (2000a). Endocannabinoids: new targets for drug development. **6**, 1361–1380.
- DI MARZO, V., BREIVOGEL, C., BISOGNO, T., MELCK, D., PATRICK, G., TAO, Q., SZALLASI, A., RAZDAN, R.K. & MARTIN, B.R. (2000b). Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. *Eur. J. Pharmacol.*, **406**, 363–374.
- DI MARZO, V. & FONTANA, A. (1995). Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. *Prostagland. Leukotr. Essent. Fatty Acids*, **53**, 1–11.
- DI MARZO, V., FONTANA, A., CADAS, H., SCHINELLI, S., CIMINO, G., SCHWARTZ, J.C. & PIOMELLI, D. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. *Nature*, **372**, 686–691.
- DI MARZO, V., GRIFFIN, G., DE PETROCELLIS, L., BRANDI, I., BISOGNO, T., WILLIAMS, W., GRIER, M.C., KULASEGRAM, S., MAHADEVAN, A., RAZDAN, R.K. & MARTIN, B.R. (2002). A structure/activity relationship study on arvanil, an endocannabinoid and vanilloid hybrid. *J. Pharmacol. Exp. Ther.*, **300**, 984–991.
- GLASER, S.T., ABUMRAD, N.A., FATADE, F., KACZOGA, M., STUDHOLME, K.M. & DEUTSCH, D.G. (2003). Evidence against the presence of an anandamide transporter. *Proc. Natl. Acad. Sci. U.S.A.*, **100**, 4269–4274.
- GUBELLINI, P., PICCONI, B., BARI, M., BATTISTA, N., CALABRESI, P., CENTONZE, D., BERNARDI, G., FINAZZI-AGRO, A. & MACCARRONE, M. (2002). Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. *J. Neurosci.*, **22**, 6900–6907.
- HILDEMAN, D.A., MITCHELL, T., TEAGUE, T.K., HENSON, P., DAY, B.J., KAPPLER, J. & MARRACK, P.C. (1999). Reactive oxygen species regulate activation-induced T cell apoptosis. *Immunity*, **10**, 735–744.
- HILLARD, C.J. & JARRAHIAN, A. (2000). The movement of N-arachidonylethanolamine (anandamide) across cellular membranes. *Chem. Phys. Lipids*, **108**, 123–134.
- HOFMANN, T.G., MOLLER, A., HEHNER, S.P., WELSCH, D., DROGE, W. & SCHMITZ, M.L. (2001). CD95-induced JNK activation signals are transmitted by the death-inducing signaling complex (DISC), but not by Daxx. *Int. J. Cancer*, **93**, 185–191.
- HUANG, S.M., BISOGNO, T., TREVISANI, M., AL-HAYANI, A., DE PETROCELLIS, L., FEZZA, F., TOGNETTO, M., PETROS, T.J., KREY, J.F., CHU, C.J., MILLER, J.D., DAVIES, S.N., GEPPETTI, P., WALKER, J.M. & DI MARZO, V. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. *Proc. Natl. Acad. Sci. U.S.A.*, **99**, 8400–8405.
- JUNG, M.Y., KANG, H.J. & MOON, A. (2001). Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. *Cancer Lett.*, **165**, 139–145.
- KIM, T.H., ZHAO, Y., BARBER, M.J., KUHASHY, D.K. & YIN, X.M. (2000). Bid-induced cytochrome *c* release is mediated by a pathway independent of mitochondrial permeability transition pore and Bax. *J. Biol. Chem.*, **275**, 39474–39481.
- KISCHKEL, F.C., HELLBARDT, S., BEHRMANN, I., GERMER, M., PAWLITA, M., KRAMMER, P.H. & PETER, M.E. (1995). Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. *EMBO J.*, **14**, 5579–5588.
- KRAMMER, P.H. (2000). CD95's deadly mission in the immune system. *Nature*, **407**, 789–795.
- KROEMER, G. & MARTINEZ, A.-C. (1994). Pharmacological inhibition of programmed lymphocyte death. *Immunol. Today*, **15**, 235–242.
- LEE, M., YANG, K.H. & KAMINSKI, N.E. (1995). Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonyl-glycerol, on immune function in B6C3F1 mouse splenocytes. *J. Pharmacol. Exp. Ther.*, **275**, 529–536.
- LEE, Y.S., NAM, D.H. & KIM, J.A. (2000). Induction of apoptosis by capsaicin in A172 human glioblastoma cells. *Cancer Lett.*, **161**, 121–130.
- LI, H., ZHU, H., XU, C.J. & YUAN, J. (1998). Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. *Cell*, **94**, 491–501.
- MACCARRONE, M., LORENZON, T., BARI, M., MELINO, G. & FINAZZI AGRO, A. (2000). Anandamide induces apoptosis in human cells *via* vanilloid receptors. Evidence for a protective role of cannabinoid receptors. *J. Biol. Chem.*, **275**, 31938–31945.
- MACHO, A., BLAZQUEZ, M.V., NAVAS, P. & MUNOZ, E. (1998). Induction of apoptosis by vanilloid compounds does not require *de novo* gene transcription and activator protein 1 activity. *Cell Growth Differ.*, **9**, 277–286.
- MACHO, A., CALZADO, M.A., MUNOZ BLANCO, J., GOMEZ DIAZ, C., GAJATE, C., MOLLINEDO, F., NAVAS, P. & MUNOZ, E. (1999). Selective induction of apoptosis by capsaicin in transformed cells: the role of reactive oxygen species and calcium. **6**, 155–165.

- MACHO, A., LUCENA, C., CALZADO, M.A., BLANCO, M., DONNAY, I., APPENDINO, G. & MUNOZ, E. (2000). Phorboid 20-homo-vanillates induce apoptosis through a VR1-independent mechanism. *Chem. Biol.*, **7**, 483–492.
- MACHO, A., LUCENA, C., SANCHE, R., DADDARIO, N., MINASSI, A., MUNOZ, E. & APPENDINO, G. (2003). Non-pungent capsaicinoids from sweet pepper synthesis and evaluation of the chemopreventive and anticancer potential. *Eur. J. Nutr.*, **42**, 2–9.
- MANSOURI, A., RIDGWAY, L.D., KORAPATI, A.L., ZHANG, Q., TIAN, L., WANG, Y., SIDDIK, Z.H., MILLS, G.B. & CLARET, F.X. (2003). Sustained activation of JNK-p38 MAP kinase pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. *J. Biol. Chem.*
- MECHOULAM, R., BEN SHABAT, S., HANUS, L., FRIDE, E., VOGEL, Z., BAYEWITCH, M. & SULCOVA, A.E. (1996). Endogenous cannabinoid ligands – chemical and biological studies. *J. Lipid Mediat. Cell. Signal.*, **14**, 45–49.
- MELCK, D., BISOGNO, T., DE PETROCELLIS, L., CHUANG, H., JULIUS, D., BIFULCO, M. & DI MARZO, V. (1999). Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. *Biochem. Biophys. Res. Commun.*, **262**, 275–284.
- MENG, X.W., HELDEBRANT, M.P. & KAUFMANN, S.H. (2002). Phorbol 12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting recruitment of Fas-associated polypeptide with death domain. *J. Biol. Chem.*, **277**, 3776–3783.
- MICHEAU, O., SOLARY, E., HAMMANN, A. & DIMANCHE-BOITREL, M.T. (1999). Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. *J. Biol. Chem.*, **274**, 7987–7992.
- MIYAWAKI, T., UEHARA, T., NIBU, R., TSUJI, T., YACHIE, A., YONEHARA, S. & TANIGUCHI, N. (1992). Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood. *J. Immunol.*, **149**, 3753–3758.
- PAROLARO, D., MASSI, P., RUBINO, T. & MONTI, E. (2002). Endocannabinoids in the immune system and cancer. *Prostagland. Leukotr. Essent. Fatty Acids*, **66**, 319–332.
- PETIT, P.X., O'CONNOR, J.E., GRUNWALD, D. & BROWN, S.C. (1990). Analysis of the membrane potential of rat- and mouse-liver mitochondria by flow cytometry and possible applications. *Eur. J. Biochem.*, **194**, 389–397.
- PUCCI, B., BELLINCAMPI, L., TAFANI, M., MASCIULLO, V., MELINO, G. & GIORDANO, A. (1999). Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation. *Exp. Cell. Res.*, **252**, 134–143.
- RICE, A.S., FARQUHAR-SMITH, W.P. & NAGY, I. (2002). Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. *Prostagland. Leukotr. Essent. Fatty Acids*, **66**, 243–256.
- RUIZ-RUIZ, C., ROBLEDO, G., FONT, J., IZQUIERDO, M. & LOPEZ-RIVAS, A. (1999). Protein kinase C inhibits CD95 (Fas/APO-1)-mediated apoptosis by at least two different mechanisms in Jurkat T cells. *J. Immunol.*, **163**, 4737–4746.
- SANCHE, R., CALZADO, M.A., DI MARZO, V., APPENDINO, G. & MUNOZ, E. (2003). Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. *Mol. Pharmacol.*, **63**, 429–438.
- SARKER, K.P., OBARA, S., NAKATA, M., KITAJIMA, I. & MARUYAMA, I. (2000). Anandamide induces apoptosis of PC-12 cells: involvement of superoxide and caspase-3. *FEBS Lett.*, **472**, 39–44.
- SCAFFIDI, C., FULDA, S., SRINIVASAN, A., FRIESEN, C., LI, F., TOMASELLI, K.J., DEBATIN, K.M., KRAMMER, P.H. & PETER, M.E. (1998). Two CD95 (APO-1/Fas) signaling pathways. *EMBO J.*, **17**, 1675–1687.
- SCAFFIDI, C., SCHMITZ, I., ZHA, J., KORSMEYER, S.J., KRAMMER, P.H. & PETER, M.E. (1999). Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. *J. Biol. Chem.*, **274**, 22532–22538.
- SMART, D., GUNTHORPE, M.J., JERMAN, J.C., NASIR, S., GRAY, J., MUIR, A.I., CHAMBERS, J.K., RANDALL, A.D. & DAVIS, J.B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). *Br. J. Pharmacol.*, **129**, 227–230.
- STERNER, O. & SZALLASI, A. (1999). Novel natural vanilloid receptor agonists: new therapeutic targets for drug development. *Trends Pharmacol. Sci.*, **20**, 459–465.
- SZALLASI, A. (2001). Vanilloid receptor ligands: hopes and realities for the future. *Drugs Aging*, **18**, 561–573.
- THORNBERRY, N.A. & LAZEBNIK, Y. (1998). Caspases: enemies within. *Science*, **281**, 1312–1316.
- TIMMER, T., DE VRIES, E.G. & DE JONG, S. (2002). Fas receptor-mediated apoptosis: a clinical application? *J. Pathol.*, **196**, 125–134.
- UEDA, N., PUFFENBARGER, R.A., YAMAMOTO, S. & DEUTSCH, D.G. (2000). The fatty acid amide hydrolase (FAAH). *Chem. Phys. Lipids*, **108**, 107–121.
- VAILLANT, F., LARM, J.A., MCMULLEN, G.L., WOLVETANG, E.J. & LAWEN, A. (1996). Effectors of the mammalian plasma membrane NADH-oxidoreductase system. Short-chain ubiquinone analogues as potent stimulators. *J. Bioenerg. Biomembr.*, **28**, 531–540.
- WALLACH, D., BOLDIN, M., VARFOLOMEEV, E., BEYAERT, R., VANDENABEELE, P. & FIEERS, W. (1997). Cell death induction by receptors of the TNF family: towards a molecular understanding. *FEBS Lett.*, **410**, 96–106.
- WOLVETANG, E.J., LARM, J.A., MOUTSOULAS, P. & LAWEN, A. (1996). Apoptosis induced by inhibitors of the plasma-membrane NADH-oxidase involves Bcl-2 and calcineurin. *Cell Growth Differ.*, **7**, 1315–1325.
- ZYGMUNT, P.M., PETERSSON, J., ANDERSSON, D.A., CHUANG, H., SORGARD, M., DI MARZO, V., JULIUS, D. & HOGESTATT, E.D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. *Nature*, **400**, 452–457.

(Received July 10, 2003
Accepted August 4, 2003)